SEC Tracker
Get the app

Madrigal Pharmaceuticals MDGL

Fred B Craves (Director) plans to sell 7,728 MDGL shares, about $2.6M

Form
144/A
Filed
Importance
Routine
Document
Form 144/A
  1. Approximate sale date: Mar 12, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Exercise of options under a registered plan

All of Fred B Craves's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 800 shares at $333.66 on Mar 12, 2025 · Form 4
  • Sold 1,951 shares at $322.45 on Mar 13, 2025 · Form 4
  • Sold 1,649 shares at $323.47 on Mar 13, 2025 · Form 4
  • Sold 900 shares at $324.69 on Mar 13, 2025 · Form 4
  • Sold 800 shares at $325.63 on Mar 13, 2025 · Form 4
  • Sold 1,000 shares at $327.63 on Mar 13, 2025 · Form 4

Written from the Form 144/A on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Madrigal Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025
  2. Repligen RGEN public float $6.0B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.